紫杉醇脂质体联合奈达铂治疗晚期食管癌的疗效观察  

Clinical observation of paclitaxel liposome plus nedaplatin in treatment of patients with advanced esophageal carcinoma.

作　　者：李启英[1] 黄露迷[2] 冀晓辉[2] 王春梅[2] 李代蓉[2] 

机构地区：[1]重庆市肿瘤医院血液肿瘤科,重庆400030 [2]重庆市肿瘤医院肿瘤内科,重庆400030

出　　处：《中国肿瘤临床与康复》2015年第11期1339-1341,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨紫杉醇脂质体联合奈达铂治疗晚期食管癌的近期疗效和不良反应。方法紫杉醇脂质体联合奈达铂方案治疗23例晚期食管癌患者,紫杉醇脂质体135mg/m2,静脉滴注3h,d1;奈达铂70mg/m2,静脉滴注,d1,每21天为1个周期,2个周期化疗后进行疗效评价。结果 23例患者中,完全缓解(CR)1例,占4.3%;部分缓解(PR)8例,占34.8%;稳定(SD)10例,占43.5%;进展(PD)4例,占17.4%;总有效率(CR+PR)为39.1%。11例初治患者总有效率为54.5%(6/11),12例复治患者总有效率为25.0%(3/12)。化疗主要不良反应为骨髓移抑制。结论紫杉醇脂质体联合奈达铂治疗晚期食管癌疗效确切且安全性好。Objective To evaluate the efficacy and adverse reactions of combined chemotherapy with paclitaxel liposome plus nedaplat in treatment of advanced esophageal cancer patients. Methods 23 patients with advanced esophageal cancer were treated with paclitaxel liposome plus nedaplat. Paclitaxel liposome 135 mg / m2 over a 3 h by intravenous infusion on day1,followed by nedaplatin 70 mg / m2. The treatment was repeated every 21 day,up to 2 cycles. Results 23 patients were evaluable for efficacy. The overall response rate（ RR） was 39. 1%（ 9 /23）,with complete response and partial response rates of 4. 3%and 34. 8%,respectively. The RR in nave patients and retreated patients were 54. 5%（ 6 /11） and 25. 0%（ 3 /12）,respectively. The major toxicities is myelosuppression. Toxicities were mild and manageable.Conclusion Paclitaxel liposome plus Nedaplat were effective and well tolerable regimens in the treatment of advanced esophageal cancer.

关 键 词：食管肿瘤 药物疗法 联合 治疗结果 

分 类 号：R735.1[医药卫生—肿瘤]